
Daniel A Ollendorf

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/486489/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018. Pharmacoeconomics, 2020, 38, 1135-1145.	3.3	109
2	Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA. Value in Health, 2019, 22, 13-20.	0.3	76
3	Growth and capacity for costâ€effectiveness analysis in Africa. Health Economics (United Kingdom), 2020, 29, 945-954.	1.7	34
4	Principles for deliberative processes in health technology assessment. International Journal of Technology Assessment in Health Care, 2020, 36, 445-452.	0.5	33
5	Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic. Health Affairs, 2021, 40, 53-61.	5.2	29
6	Using QALYs versus DALYs to measure cost-effectiveness: How much does it matter?. International Journal of Technology Assessment in Health Care, 2020, 36, 96-103.	0.5	26
7	Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society. Cephalalgia, 2021, 41, 279-293.	3.9	24
8	Do Cost-Effectiveness Analyses Account for Drug Genericization? A Literature Review and Assessment of Implications. Value in Health, 2022, 25, 59-68.	0.3	13
9	An Evidence Review of Low-Value Care Recommendations: Inconsistency and Lack of Economic Evidence Considered. Journal of General Internal Medicine, 2021, 36, 3448-3455.	2.6	12
10	Considering and communicating uncertainty in health technology assessment. International Journal of Technology Assessment in Health Care, 2021, 37, e74.	0.5	11
11	Drug-Pricing Debate Redux — Should Cost-Effectiveness Analysis Be Used Now to Price Pharmaceuticals?. New England Journal of Medicine, 2021, 385, 1923-1924.	27.0	11
12	Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force. Value in Health, 2022, 25, 869-886.	0.3	11
13	Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States. Pharmacoeconomics, 2019, 37, 1321-1327.	3.3	8
14	Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model. Value in Health, 2019, 22, 416-422.	0.3	8
15	Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic. Pharmacoeconomics, 2021, 39, 1201-1208.	3.3	8
16	Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force. International Journal of Technology Assessment in Health Care, 2022, 38, .	0.5	8
17	Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists. European Journal of Health Economics, 2021, 22, 723-733.	2.8	7
18	The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 782-785.	0.9	5

DANIEL A OLLENDORF

#	Article	IF	CITATIONS
19	Bridging the gap: aligning economic research with disease burden. BMJ Global Health, 2021, 6, e005673.	4.7	5
20	Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines. Vaccine, 2021, 39, 6727-6734.	3.8	5
21	The Impact of Broader Value Elements on Cost-Effectiveness Analysis: Two Case Studies. Value in Health, 2022, 25, 1336-1343.	0.3	4
22	Does the Institute for Clinical and Economic Review Revise Its Findings in Response to Industry Comments?. Value in Health, 2019, 22, 1396-1401.	0.3	3
23	Valueâ€based drug pricing in the Biden era: Opportunities and prospects. Health Services Research, 2021, 56, 1093-1099.	2.0	3
24	Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pretreated relapsed and refractory multiple myeloma. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 1315-1320.	0.9	3
25	Herd Immunity Effects in Cost-Effectiveness Analyses among Low- and Middle-Income Countries. Applied Health Economics and Health Policy, 2022, , 1.	2.1	3
26	Burning Issues in Health Technology Assessment and Policy Making: What's Keeping Senior Health Technology Assessment Users and Producers up at Night?. International Journal of Technology Assessment in Health Care, 2020, 36, 5-7.	0.5	2
27	Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy. BMJ Open, 2021, 11, e046707.	1.9	2
28	The Supercar Stays in the Garage: Factors Preventing Indirect Comparisons of Novel Medicines Targeting the Same Condition. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 333-334.	0.9	0
29	Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 1046-1055.	0.9	0
30	Is Value Portable? An Examination of Contextual and Practical Considerations that Affect the Transferability of Value Assessments between Settings. International Journal of Technology Assessment in Health Care, 2022, , 1-26.	0.5	0